臨床婦人科産科72巻2号

2018年03月発行

今月の臨床 ホルモン補充療法ベストプラクティス─いつから始める？　いつまで続ける？　何に注意する？ 悪性腫瘍との関連

BRCA遺伝子変異を有する女性へのHRT

著者： 髙松潔¹ 橋本志歩¹ 杉山重里¹ 小川真里子¹

所属機関： ¹東京歯科大学市川総合病院産婦人科

ページ範囲：P.272 - P.277

●乳がんの既往がなく，発症もしていないBRCA遺伝子変異を有する女性へのHRTは，一般女性へのHRT同様に有用である．

●現在までのところ，これらの女性へのHRT施行により，乳がん・卵巣がん・子宮内膜がんリスクの上昇を示唆する報告はない．

●BRCA遺伝子変異を有する女性に対しては，RRSO後や自然閉経後の諸症状・疾患に対し，あるいはヘルスケアの目的でHRTの可能性を提示することはQOLの維持・向上の点から必須であると考えられる．

参考文献

1）Kuchenbaecker KB, et al : Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317 : 2402─2416, 2017

2）日本HBOCコンソーシアム広報委員会 : 遺伝性乳がん卵巣がん症候群（HBOC）をご理解いただくために（Ver.3）．http://hboc.jp/downloads/pamphlet_ver3.pdf（2017年6月27日アクセス）

3）Finch AP, et al : Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32 : 1547─1553, 2014

4）National Comprehensive Cancer Network : Genetic/Familial High-risk assessment Breast and Ovarian Version 2. 2017　https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf（2017年6月27日アクセス）

5）Finch A, et al : Hereditary Breast Cancer Study Group : Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 99 : 1724─1728, 2013

6）de Villiers TJ, et al : Revised global consensus statement on menopausal hormone therapy. Climacteric 19 : 313─315, 2016

7）日本産科婦人科学会・日本女性医学学会 : ホルモン補充療法ガイドライン2017年度版．日本産科婦人科学会，2017

8）髙松　潔，他 : ホルモン補充療法の対象者　ヘルスケアとしての広がりと将来．週刊日本医事新報4865 : 39─50, 2017

9）Johansen N, et al : Sexual activity and functioning after risk-reducing salpingo-oophorectomy : impact of hormone replacement therapy. Gynecol Oncol 140 : 101─106, 2016

10）Rocca WA, et al : Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69 : 1074─1083, 2007

11）Rebbeck TR, et al : Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 : 1475─1479, 1999

12）Rebbeck TR, et al : PROSE Study Group : Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers : the PROSE Study Group. J Clin Oncol 23 : 7804─7810, 2005

13）Domchek SM, et al : Is hormone replacement therapy（HRT） following risk-reducing salpingo-oophorectomy（RRSO） in BRCA1（B1） - and BRCA2（B2） -mutation carriers associated with an increased risk of breast cancer? J Clin Oncol 29（suppl）: Abstract 1501, 2011

14）Gabriel CA, et al : Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer 8 : 23─28, 2009

15）Eisen A, et al : Hereditary Breast Cancer Clinical Study Group : Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100 : 1361─1367, 2008

16）Kotsopoulos J, et al : Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers : a case-control study. Breast Cancer Res Treat 155 : 365─373, 2016

17）Armstrong K, et al : Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations : a decision analysis. J Clin Oncol 22 : 1045─1054, 2004

18）Collaborative Group on Epidemiological Studies of Ovarian Cancer : Menopausal hormone use and ovarian cancer risk : individual participant meta-analysis of 52 epidemiological studies. Lancet 385 : 1835─1842, 2015

19）Kotsopoulos J, et al : Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100 : 83─88, 2006

20）Segev Y, et al : Hereditary Breast Cancer Study Group : Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation : a case control study. Fam Cancer 14 : 383─391, 2015

21）North American Menopause Society : Use of systemic hormone therapy in BRCA mutation carriers　http://www.menopause.org/docs/default-source/professional/nams-practice-pearl-brca-and-ht.pdf（2017年6月27日アクセス）

22）The American College of Obstetricians and Gynecologists : Committee opinion No.698 : Hormone therapy in primary ovarian insufficiency. Obstet Gynecol 129 : e134─e141, 2017

23）National Institute for Health and Care Excellence : Familial breast cancer : classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE guidelines［CG164］，2013（Last updated March 2017）　https://www.nice.org.uk/guidance/cg164/chapter/1-recommendations#risk-reduction-and-treatment-strategies（2017年6月27日アクセス）

24）Birrer N, et al : Is hormone replacement therapy safe in women with a BRCA Mutation? : a systematic review of the contemporary literature. Am J Clin Oncol, 2016［Epub ahead of print］

25）Nappi RE, et al : Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer. Minerva Ginecol 68 : 602─612, 2016